Recombinant factor concentrates may increase inhibitor development: A single centre cohort study

Haemophilia

Volumn 17, Issue 4, 2011, Pages 625-629

  Strauss, T ^a   Lubetsky, A ^a   Ravid, B ^a   Bashari, D ^a   Luboshitz, J ^a   Lalezari, S ^a   Misgav, M ^b   Martinowitz, U ^a   Kenet, G ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Haemophilia; Inhibitor; Plasma derived products; Recombinant factor

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTICLE; BLEEDING; CHILD; CIRCUMCISION; FOLLOW UP; HEMOPHILIA A; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; AUTOANTIBODIES; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FACTOR VIII; FEMALE; HEMOPHILIA A; HUMANS; INFANT; ISRAEL; MALE; RECOMBINANT PROTEINS;

EID: 79959529406     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02464.x     Document Type: Article

References (30)

1. Fischer K, van der Bom JG, Mauser-Bunschoten EP et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 2001; 7: 446-52.
2. Nilsson IM, Berntorp E, Löfqvist T et al. Twenty-five years' experience of prophylactic treatment in severe hemophilia A and B. J Intern Med 1992; 232: 25-32.
3. Calvez T, Laurian Y, Goudemand J. Inhibitor incidence with recombinant vs. Plasma-derived FVIII in previously untreated patients with severe hemophilia A: homogenous results from for published observational studies. J Thromb Haemost 2008; 6: 390-2.
4. Chalmers EA, Brown SA, Keeling D et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13: 149-55.
5. Ehrlich HJ, Bray GL, Gomperts ED. Comparison of high responder inhibitor frequency in recent studies of previously untreated patients with hemophilia A. Thromb Haemost 1998; 79: 242-3.
6. Gill FM. The natural history of factor VIII inhibitors in patients with hemophilia A. In: Hoyer LW ed. Factor VIII inhibitors. New York: Alan R Liss, 1984: 19-29.
7. Gouw SC, van der Bom JG, Auerswald G et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109: 4693-7.
8. Gouw SC, van den Berg HM, le Cessie S et al. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007; 5: 1383-90.
9. Morado M, Villar A, Jimenez Yuste V et al. Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia 2005; 11: 79-83.
10. Schwaab R, Brackmann HH, Meyer C et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
11. Sharathkumar A, Lillicrap D, Blanchette VS et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1: 1228-36.
12. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
13. Addiego J, Kasper C, Abildgaard C et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993; 342: 462-4.
14. Briet E, Rosendaal FR, Kreuz W et al. High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products. Thromb Haemost 1994; 72: 1620-4.
15. Courter SG, Bedrosian CL. Clinical evaluation of B-Domain deleted recombinant factor VIII in previously untreated patients. Sem Hematol 2001; 38: 52-9.
16. De Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, De Blasi D. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost 1994; 71: 544-7.
17. Gringeri A, Monzini M, Tagariello G et al. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate. Haemophilia 2006; 12: 128-32.
18. Lusher JM, Arkin S, Abildgaard CF et al. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. New Engl J Med 1993; 328: 453-9.
19. Peerlinck K, Rosendaal FR, Vermylen J. Incidence of inhibitor development in a group of young hemophilia patients treated exclusively with lyophilized cryoprecipitate. Blood 1993; 81: 3332-5.
20. Iorio A, Halimeh S, Holzhauer S et al. Rate of inhibitor development in previously-untreated hemophilia a patients treated with plasma-derived or recombinant factor VIII concentrates. A systematic review. J Thromb Haemost 2010; 8: 1256-65.
21. Escuriola Ettingshausen C, Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 2006; 12: S102-6.
22. Goudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
23. Kreuz W, Escuriola Ettingshausen C, Zyschka A et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Sem Thromb Haemost 2002; 28: 285-90.
24. Rothschild C, Laurian Y, Satre EP et al. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: Incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 1998; 80: 779-83.
25. Strauss T, Ravid B, Martinowitz U et al. Early exposure to recombinant factor concentrates may increase inhibitor development: a single center cohort study. Haemophilia 2008; 14(Suppl. 2): 52.
26. Blanchette VS. Prophylaxis in the haemophilia population. Haemophilia 2010; 16(Suppl 5): 181-8.
27. Miners AH, Sabin CA, Tolley KH et al. Primary prophylaxis for individuals with severe haemophilia: how many hospital visits could treatment prevent? J Int Med 2000; 247: 493-9.
28. Lorenzo JI, López A, Altisent C et al. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113: 600-3.
29. Yee TT, Williams MD, Hill FGH et al. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a singe intermediate purity factor VIII product. Thromb Haemost 1997; 78: 1027-9.
30. Kurnik K, Bidlingmaier C, Engl W et al. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010; 16: 256-62.